hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06288711, orgStudyIdInfo id: CHRBSS #STUDY00002538, secondaryIdInfos id: R01DA057308, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DA057308, briefTitle: Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2027-08-31, completionDateStruct date: 2027-11-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: University of Vermont, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD., conditionsModule conditions: Opioid Use Disorder, conditions: Posttraumatic Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 135, type: ESTIMATED, armsInterventionsModule interventions name: Prolonged exposure therapy, interventions name: Financial incentives, interventions name: Treatment as usual, outcomesModule primaryOutcomes measure: Prolonged exposure therapy session attendance, primaryOutcomes measure: Prolonged exposure therapy completion, primaryOutcomes measure: Change in posttraumatic stress disorder symptom severity - clinician rated, secondaryOutcomes measure: Change in non-prescribed drug use - objective, secondaryOutcomes measure: Change in non-prescribed drug use - self-reported, secondaryOutcomes measure: Change in opioid craving, secondaryOutcomes measure: Medications for opioid use disorder treatment retention, secondaryOutcomes measure: Prolonged exposure therapy acceptability, secondaryOutcomes measure: Satisfaction with prolonged exposure therapy delivered via telemedicine, secondaryOutcomes measure: Prolonged exposure therapy homework adherence, secondaryOutcomes measure: Change in posttraumatic stress disorder symptom severity - self-reported, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Vemont, status: RECRUITING, city: Burlington, state: Vermont, zip: 05401, country: United States, contacts name: Kelly R Peck, Ph.D., role: CONTACT, phone: 802-656-9610, email: Kelly.Peck@uvm.edu, geoPoint lat: 44.47588, lon: -73.21207, hasResults: False
protocolSection identificationModule nctId: NCT06288698, orgStudyIdInfo id: 53955721, briefTitle: Understanding Patient Engagement Trends in TBI Clinical Research, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Power Life Sciences Inc., class: INDUSTRY, descriptionModule briefSummary: Clinical trials, specifically focused on TBI, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients., conditionsModule conditions: TBI, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, outcomesModule primaryOutcomes measure: Number of TBI patients who decide to enroll in a clinical research, primaryOutcomes measure: Rate of TBI patients who remain in clinical trial to trial completion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Power Life Sciences, city: San Francisco, state: California, zip: 94107, country: United States, contacts name: Michael B Gill, role: CONTACT, phone: 415-900-4227, email: https://www.withpower.com/contact-us@withpower.com, geoPoint lat: 37.77493, lon: -122.41942, documentSection largeDocumentModule largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-02-23, uploadDate: 2024-02-23T11:01, filename: ICF_000.pdf, size: 69900, hasResults: False
protocolSection identificationModule nctId: NCT06288659, orgStudyIdInfo id: KY2024-050, briefTitle: aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial, acronym: ASTIM-MT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Huashan Hospital, class: OTHER, descriptionModule briefSummary: ASTIM is a multicenter, prospective, randomised, blinded end-point assessed trial, to investigate the efficacy and safety of treatment based on intracranial pressure monitoring in improving the prognosis of patients with aneurysmal subarachnoid hemorrhage., conditionsModule conditions: Aneurysmal Subarachnoid Hemorrhage, conditions: Intracranial Pressure Increase, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 368, type: ESTIMATED, armsInterventionsModule interventions name: Intraventricular intracranial pressure monitoring, outcomesModule primaryOutcomes measure: The rate of good neurological functional prognosis, secondaryOutcomes measure: The rate of good neurological functional prognosis, secondaryOutcomes measure: The rate of good prognosis by Glasgow Outcome Scale-Extended (GOS-E), secondaryOutcomes measure: Mortality, secondaryOutcomes measure: Incidence of VP shunt-related hydrocephalus, secondaryOutcomes measure: Incidence of Delayed Cerebral Ischemia, secondaryOutcomes measure: Incidence of epilepsy, otherOutcomes measure: Incidence of intracranial infection, otherOutcomes measure: Incidence of bleeding from puncture site, otherOutcomes measure: Incidence of poor healing in surgical incisions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Neurosurgery, Huashan Hospital, Fudan University, city: Shanghai, state: Shanghai, zip: 200000, country: China, contacts name: Xuehai Wu, Ph.D., role: CONTACT, phone: +8613764880571, email: wuxuehai2013@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06288646, orgStudyIdInfo id: ROMEO 101712, briefTitle: Using Infrared Spectroscopy to Analyze Volatile Organic Compounds (VOCs) in the Breath of Patients With Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-24, primaryCompletionDateStruct date: 2024-04-24, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Picomole Inc, class: INDUSTRY, collaborators name: Vitalite Health Network, descriptionModule briefSummary: The goal of this clinical trial is to compare breath samples from patients with lung cancer, those with stable lung nodules, and individuals without lung cancer. The main questions it aims to answer are whether breath patterns are different in these groups and to see if breath patterns change after treatment in patients with lung cancer.Participants will be asked to provide one breath sample, and two if they get treated. They will also be asked to fill out a questionnaire about their background and medical history., conditionsModule conditions: Lung Cancer, conditions: Non Small Cell Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Differences in Breath Spectra of Lung Cancer, Stable Pulmonary Nodules, and Controls, secondaryOutcomes measure: Differences in breath spectra of patients with lung cancer before and after treatment, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vitalite Health Network, status: RECRUITING, city: Moncton, state: New Brunswick, zip: E1C 8X3, country: Canada, contacts name: Nada Hammami, role: CONTACT, phone: 506-869-7391, email: Nada.Hammami@Vitalitenb.ca, contacts name: Marcel Mallet, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 46.09454, lon: -64.7965, hasResults: False
protocolSection identificationModule nctId: NCT06288620, orgStudyIdInfo id: MA-EBC-II-024, briefTitle: Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2025-05-10, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Microwave Ablative (MWA) therapy, as a minimally invasive thermal therapy, has been attempted to treat breast cancer of small lesions . However, the optimal indications for MWA in the treatment of breast cancer is unknown. This prospective, open-label, single-arm phase II clinical study was conducted to evaluate the efficacy and safety of MWA in the treatment of early-stage unifocal invasive breast cancer, and to explore the immune activating effect., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 77, type: ESTIMATED, armsInterventionsModule interventions name: Microwave Ablation, outcomesModule primaryOutcomes measure: Complete ablation rate, secondaryOutcomes measure: Safety of microwave ablation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the First Affiliated Hospital of Nanjing Medical University, status: RECRUITING, city: Nanjing, state: Jiangsu, country: China, contacts name: Wenbin Zhou, Professor, role: CONTACT, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06288607, orgStudyIdInfo id: 2023-SR-708, briefTitle: Safety and Efficacy of High Intensity Focused Ultrasound in Solar Lentigo: A Self-controlled Study, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-16, primaryCompletionDateStruct date: 2024-04-18, completionDateStruct date: 2024-04-18, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: This trial is a single-center, prospective self-controlled study. The study proposes to recruit 30 patients with solar lentigo on both sides of the face. Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated. The Lab\* values of the lesion area and the area around the lesion are detected separately using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and skin lesion images are collected with dermatoscope and VISIA® (Canfield Company, USA). Measurements of Lab\* values and related images at the same location, along with adverse events, physician and subjective global aesthetic improvement scale scores are recorded before and at week2, week 4, week6. At the end of the follow-up on the treatment side, the same parameter treatment is provided for the untreated side, and the corresponding observation items are recorded for the patient before treatment, and at week2, week4, and week6 respectively., conditionsModule conditions: Solar Lentigo, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China), outcomesModule primaryOutcomes measure: Lab* values, primaryOutcomes measure: Physician Global Aesthetic Improvement Scale, primaryOutcomes measure: Subjective Global Aesthetic Improvement Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, city: Nanjing, state: Jiangsu, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06288581, orgStudyIdInfo id: UDDS-Pedo-02-2024, briefTitle: U Shaped Toothbrush in Removing Plaque in Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Damascus University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effectiveness of a U-shaped toothbrush in removing plaque in preschool children which can be a simple, acceptable, and effective way to remove plaque in children in order to improve their oral health in the absence of parental supervision.Children accepted in the study will be randomly divided into two groups:The traditional toothbrush group and the U-shaped toothbrush group, All children aged four to five years will have their plaque assessed with the Turesky Modified Quigley Hein Index (TMQH), conditionsModule conditions: Dental Plaque, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Traditional toothbrush group, interventions name: U shaped toothbrush group, outcomesModule primaryOutcomes measure: Changing in plaque index, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: Damascus University, status: RECRUITING, city: Damascus, zip: 20872, country: Syrian Arab Republic, contacts name: Kamar Abdulrahman, MSc. student, role: CONTACT, phone: 00963957510093, email: kamarabdulrahman1@gmail.com, geoPoint lat: 33.5102, lon: 36.29128, hasResults: False
protocolSection identificationModule nctId: NCT06288555, orgStudyIdInfo id: 020/2566, briefTitle: Validation of Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening in Primary Care, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-21, primaryCompletionDateStruct date: 2024-01-23, completionDateStruct date: 2024-01-23, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Ponlawat Hanchana, MD, class: OTHER_GOV, descriptionModule briefSummary: The goal of this observational study is to assess the accuracy of screening for diabetic peripheral neuropathy by comparing the Ipswich touch test with the 10-g monofilament test in patients diagnosed with type 2 diabetes.The main question it aims to answer is:How does the accuracy of the Ipswich Touch Test for identifying peripheral neuropathy compare to the traditional 10-g monofilament test?Participants underwent both the Ipswich touch test and the 10-g monofilament test., conditionsModule conditions: Diabetic Foot, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 274, type: ACTUAL, armsInterventionsModule interventions name: Ipswich touch test, outcomesModule primaryOutcomes measure: The accuracy of the Ipswich touch test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ponlawat Hanchana, MD, city: Saraburi, zip: 18120, country: Thailand, geoPoint lat: 14.53333, lon: 100.91667, hasResults: False
protocolSection identificationModule nctId: NCT06288542, orgStudyIdInfo id: MD-250-2022, briefTitle: Preoperative Dextrose Infusion and Postoperative Nausea and Vomiting, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: This research aims to investigate the efficacy of preoperative intravenous infusion of dextrose 5% during fasting in lowering the incidence and severity of post-operative nausea and vomiting related to laparoscopic gynaecologic procedures, conditionsModule conditions: Effect of Dextrose on Postoperative Nausea and Vomiting, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 111, type: ESTIMATED, armsInterventionsModule interventions name: group d, interventions name: group R, outcomesModule primaryOutcomes measure: frequency of post-opertive nausea and vomiting in 24 hour, secondaryOutcomes measure: TOTAL AMOUNT OF ANTIEMETIC REQUIRED, eligibilityModule sex: FEMALE, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06288529, orgStudyIdInfo id: 1, briefTitle: EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-15, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-01-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of Health Sciences Balikesir Hospital Eduation and Research, class: OTHER_GOV, descriptionModule briefSummary: Chronic kidney disease and type 2 diabetes mellitus patients are with in high-risk patients in coronary arterial diseases and increasing number of coronary angiography and coronary interventional procedures have been performed in these population. As well as the risk factors have been identified by many studies preventive measures are lacking.In our study we found that SGLT2 inhibitors are beneficial in terms of reducing contrast media induced acute kidney injury in both diabetic and CKD patients.This is one of the leading studies in the literature pointing that SGLT2 inhibitors may have a potentially beneficial role in reducing or preventing the development of PC-AKI., conditionsModule conditions: Chronic Kidney Diseases, conditions: Type2diabetes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 975, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Development of post-contrast acute kidney injury, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Health Sciences Balikesir Education and Research Hospital, city: Balıkesir, zip: 10100, country: Turkey, geoPoint lat: 39.64917, lon: 27.88611, hasResults: False
protocolSection identificationModule nctId: NCT06288503, orgStudyIdInfo id: HRF2023, briefTitle: Hydrolysed Rice Formula Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2027-07, completionDateStruct date: 2027-07, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Nutricia UK Ltd, class: INDUSTRY, descriptionModule briefSummary: This non-inferiority study aims to determine whether a hydrolysed rice protein formula is as effective as a cow's milk protein based extensively hydrolysed formula using a double-blind, randomised-controlled design over a 28-day intervention period followed by a 2-month follow-up period in infants 0-13 months of age presenting with symptoms/clinical history suggestive of cow's milk allergy. The primary outcome is growth, and secondary outcomes are gastrointestinal tolerance, and differences in intake, allergic symptoms, parental QOL, acceptability, dietary intake, and safety., conditionsModule conditions: Cow's Milk Protein Allergy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 86, type: ESTIMATED, armsInterventionsModule interventions name: Hydrolysed Rice Protein Formula, interventions name: Cow's Milk Based Extensively Hydrolysed Formula, outcomesModule primaryOutcomes measure: Growth, secondaryOutcomes measure: Gastrointestinal Tolerance, secondaryOutcomes measure: Stool frequency and consistency, secondaryOutcomes measure: Study Product Intake, secondaryOutcomes measure: Patient Orientated Scoring Atopic Dermatitis Symptoms (PO-SCORAD), secondaryOutcomes measure: Patient Reported Atopic Symptoms, secondaryOutcomes measure: Cow's Milk Related Symptom Score, secondaryOutcomes measure: Food Allergy Quality of Life-Parental Burden (FAQL-PB), secondaryOutcomes measure: Acceptability of the Study Formula, secondaryOutcomes measure: Nutrient Intake (Energy, Protein, Micronutrients), secondaryOutcomes measure: Dietetic Goal, secondaryOutcomes measure: Overall Safety, eligibilityModule sex: ALL, minimumAge: 0 Months, maximumAge: 13 Months, stdAges: CHILD, contactsLocationsModule locations facility: Gloucestershire Royal NHS Trust, status: RECRUITING, city: Gloucester, state: Gloucestershire, zip: GL1 3NN, country: United Kingdom, contacts name: Victoria Bittle, role: CONTACT, phone: 0300 422 5506, email: v.bittle@nhs.net, geoPoint lat: 51.86568, lon: -2.2431, locations facility: Bristol Royal Hospital for Children, status: RECRUITING, city: Bristol, state: Somerset, zip: BS16 1TA, country: United Kingdom, contacts name: Sarah Trace, role: CONTACT, phone: 0117 3428802, email: sarah.trace@uhbw.nhs.uk, geoPoint lat: 51.45523, lon: -2.59665, hasResults: False